---
title: 'Industry Daily Summary: What Happened on November 19, 2026'
headline: Johnson & Johnson agrees to buy Ollin for up to $3.3 billion
description: California biopharma layoffs affected at least 1,176 workers, while AbbVie
  and DISCO agreed to a cancer-drug discovery deal worth up to $2.5 billion.
url: https://thebench.bio/news/industry/2026-11-19
topic: industry
date: '2026-11-19'
covers:
- '2026-11-19'
date_published: '2026-11-19T12:04:46Z'
date_modified: '2026-11-19T12:04:46Z'
tags:
- Industry
- Research
sources: 6
publisher: TheBench.Bio
---

# Industry Daily Summary: What Happened on November 19, 2026

**Johnson & Johnson agrees to buy Ollin for up to $3.3 billion**

California biopharma layoffs affected at least 1,176 workers, while AbbVie and DISCO agreed to a cancer-drug discovery deal worth up to $2.5 billion.

## Today in brief

Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront, with as much as $1.125 billion more tied to regulatory and commercial milestones. [1] Ollin’s Phase III antibody OLN324 targets retinal diseases. [1] BioSpace counted at least 1,176 workers affected by cuts announced or projected by 24 California biopharma companies this year. [2]

AbbVie will pay DISCO Pharmaceuticals $40 million upfront to discover cancer drugs, with additional payments and royalties possible. [3]

## Johnson & Johnson adds a Phase III eye drug through an Ollin buyout

Johnson & Johnson agreed on November 16 to acquire Ollin Biosciences for $2.2 billion upfront, plus as much as $1.125 billion in regulatory and commercial milestones. [1] Ollin’s lead candidate, OLN324, is an investigational bispecific antibody in Phase III for wet age-related macular degeneration and diabetic macular edema. [1]

OLN324’s clinical differentiation, regulatory path and commercial adoption remain uncertain. [1] Separately, Johnson & Johnson announced $750 million in development financing from Blackstone Life Sciences, along with contingent payments and royalties. [1]

## At least 1,176 workers affected by California biopharma cuts

BioSpace counted at least 1,176 workers affected by layoffs announced or projected by 24 California biopharma companies during 2026. [2] Nine companies were cutting at least half their workforces, and two had closed. [2]

Gilead had the largest reported California cuts, affecting 193 workers, including 108 Arcellx employees laid off in June. [2] Artiva Biotherapeutics said it would stop developing its lead candidate and cut about 94% of its employees after two patient deaths and concerns about response durability. [2] In August, aTyr Pharma said it would cut about 60% of its staff to focus resources on efzofitimod for interstitial lung disease. [2]

## AbbVie offers DISCO up to $2.5 billion for cancer-drug discovery

AbbVie will pay DISCO Pharmaceuticals $40 million upfront for cancer-drug discovery research. [3] DISCO may also receive as much as $2.5 billion in payments tied to options, development and other milestones, plus tiered royalties on global net sales. [3]

After specified research, AbbVie may take exclusive licenses to selected programs for further development. [3] DISCO’s platform searches for pairs of proteins found together on cancer cells but less often together on healthy tissue. [3]

## Also worth knowing

- Genomics Limited and Vertex Pharmaceuticals extended their drug-discovery partnership by four years. Genomics says the agreement could exceed $220 million through milestones and royalties. [4] [5]
- Merck and Isomorphic Labs will search for small-molecule candidates against an undisclosed cancer target. Merck will handle development, manufacturing and commercialization of any resulting products. [6]

## The day in numbers

- **$2.2 billion upfront**: Johnson & Johnson’s agreed payment to acquire Ollin Biosciences, before up to $1.125 billion in milestones. [1]
- **1,176 workers**: At least this many people were affected by announced or projected cuts at California biopharma companies in 2026, according to BioSpace’s tally. [2]
- **$40 million**: AbbVie’s upfront payment to DISCO Pharmaceuticals for cancer-drug discovery work. [3]

## Also published

- [MHRA appoints senior NHS executive as new Chief Finance and Commercial Officer](<https://www.gov.uk/government/news/mhra-appoints-senior-nhs-executive-as-new-chief-finance-and-commercial-officer>), MHRA
- [Multiple sclerosis market expected to reach $33.0bn across the 7MM by 2034](<https://www.pharmaceutical-technology.com/analyst-comment/multiple-sclerosis-market-7mm-2034/>), Pharmaceutical Technology
- [Progress with NHS England pilots of alternative funding approaches](<https://pharmaphorum.com/market-access/progress-nhs-england-pilots-alternative-funding-approaches>), pharmaphorum
- [A new chapter for GeneCore](<https://www.embl.org/news/people-perspectives/a-new-chapter-for-genecore/>), EMBL
- [Ramping up: 3 biotechs growing their workforce after series C raises](<https://www.biospace.com/job-trends/ramping-up-3-biotechs-growing-their-workforce-after-series-c-raises>), BioSpace

## Sources

1. [Johnson & Johnson's Strategic Shift: Why Diversification Is Giving Way to Focus](<https://www.pharmexec.com/view/pharmaceutical-company-strategy-johnson-johnson-diversification>), Pharmaceutical Executive, 2026-11-19
2. [9 biotechs will cut at least half their California workforces](<https://www.biospace.com/job-trends/9-biotechs-will-cut-at-least-half-their-california-workforces>), BioSpace, 2026-11-19
3. [After Amgen, DISCO lands AbbVie deal worth up to $2.5B](<https://european-biotechnology.com/latest-news/after-amgen-disco-lands-abbvie-deal-worth-up-to-2-5b/>), European Biotechnology, 2026-11-19
4. [Oxford-based Genomics keeps Vertex on board for another four years, potential $220M deal](<https://european-biotechnology.com/latest-news/oxford-based-genomics-keeps-vertex-on-board-for-another-four-years-potential-220m-deal/>), European Biotechnology, 2026-11-19
5. [Genomics, Vertex extend drug discovery alliance in $220m deal](<https://www.pharmaceutical-technology.com/news/genomics-vertex-extend-alliance-220m-deal/>), Pharmaceutical Technology, 2026-11-19
6. [Merck, Isomorphic Labs partner to develop oncology drug candidates](<https://www.statnews.com/2026/11/19/merck-isomorphic-labs-partner-to-develop-oncology-drug-candidates/?utm_campaign=rss>), STAT Biotech, 2026-11-19

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.pharmexec.com/view/pharmaceutical-company-strategy-johnson-johnson-diversification>
[2]: <https://www.biospace.com/job-trends/9-biotechs-will-cut-at-least-half-their-california-workforces>
[3]: <https://european-biotechnology.com/latest-news/after-amgen-disco-lands-abbvie-deal-worth-up-to-2-5b/>
[4]: <https://european-biotechnology.com/latest-news/oxford-based-genomics-keeps-vertex-on-board-for-another-four-years-potential-220m-deal/>
[5]: <https://www.pharmaceutical-technology.com/news/genomics-vertex-extend-alliance-220m-deal/>
[6]: <https://www.statnews.com/2026/11/19/merck-isomorphic-labs-partner-to-develop-oncology-drug-candidates/?utm_campaign=rss>
